公开(公告)号：US20230045015A1

公开(公告)日：2023-02-09

申请号：US17639929

申请日：2020-08-28

申请人： zhankai QI ,  Hyatt QI

发明人： zhankai QI ,  Hyatt QI

IPC分类号： A61K38/17 ,  A61P13/12

摘要： With years of disease progression, a small amount of albumin in the blood of nephropathy patients started to leak into the urine, however very likely to be ignored due to mild clinical symptoms or confused with proteinuria caused by hypertension and/or hyperlipidemia with progress. But when other biomarkers of renal function are also found significantly increased in urine, such as β2 microglobulin α1 microglobulin, transferrin and immunoglobulin, the renal function has been impacted by pathological changes. At present, there is no effective method except hormone for nephropathy proteinuria treatment, and long-term hormone treatment will bring many side effects to patients. If the course of disease progresses freely, more protein will leak into the urine, and the renal damage will be getting worse. Cobrotoxin polypeptide molecule can effectively reduce the leakage/proteinuria, control and delay the renal pathological progression and improve renal function by inhibiting the autoimmune inflammatory response of kidney, thus contribute significantly to the treatment of nephropathy.

公开(公告)号：US20240245757A1

公开(公告)日：2024-07-25

申请号：US18216636

申请日：2023-07-27

申请人： Zhankai Qi

发明人： Zhankai Qi

IPC分类号： A61K38/46 ,  A61P13/02

CPC分类号： A61K38/465 ,  A61P13/02 ,  C12Y301/01004

摘要： The invention relates to a pharmaceutical composition, which comprises Elapidae Phospholipase A2 and a pharmaceutically acceptable carrier thereof. This pharmaceutical composition can be used for the treatment of micro proteinuria and renal disfunction with increased ratio of urinary albumin vs creatinine of diabetes nephropathy patients, thereby controlling and delaying the pathological progress of kidney, improving the renal function, and has extremely potential for the treatment of diabetes nephropathy.

公开(公告)号：US20210008177A1

公开(公告)日：2021-01-14

申请号：US16812529

申请日：2020-03-09

申请人： Zhankai Qi ,  Hyatt Qi

发明人： Zhankai Qi ,  Hyatt Qi

IPC分类号： A61K38/48 ,  A61P25/00

摘要： Provided herein is elapidae neurotoxin, and methods for using a pharmaceutically effective amount of said compound to produce synergistic analgesic effect with an opioid for the treatment of pain. In addition, opioid induced hyperalgesia and tolerance can also be alleviated by said compound while administrated separately, or jointly with the opioid.

公开(公告)号：US20200093866A1

公开(公告)日：2020-03-26

申请号：US16403651

申请日：2019-05-06

申请人： zhankai Qi

发明人： zhankai Qi

IPC分类号： A61K35/583 ,  A61K38/17 ,  A61K9/00 ,  A61P25/04

摘要： A composition of matter for an analgesia and its method of use is disclosed. The composition comprises selected single cobrotoxin molecule which is characterized by its high affinity binding to nicotinic acetylcholine receptors, rapid onset, and better safety profile comparing to a cobrotoxins complexes. The method of use is for the treatment of pain, especially for the treatment of refractory pain as associated with advanced cancer, rheumatoid arthritis, chronic neuropathic, migraine, and viral infections.